

Review of: "New Druggable Targets for Rheumatoid Arthritis Based on Insights From Synovial Biology"

Sagarika Biswas¹

¹ Institute of Genomics and Integrative Biology

Potential competing interests: The author(s) declared that no potential competing interests exist.

Comments

The title of the review is very broad. The studies in the following area must have been incorporated.

- 1) The review should have included few non-coding RNA like miRNA, piRNA, circRNA AND lncRNA as advanced drug targets of RA. Some miRNAs as a drug are already under clinical trial, it should have been mentioned as a new targets of RA.
- 2) The area of proteomic studies in disease condition has also been progressing fast leading to very important differential proteins/genes causing pathogenicity in RA. The advanced drugs targeting these differential proteins must have been incorporated. Recently the advanced proteomic study leading to exposure of RA pathogenicity are also reported and is greatly missing in this review article. It must be incorporated.
- 3) Cross-kingdom regulation approach must have been also incorporated since this is also new emerging field and the role of exogenous miRNAs are predicted and validated in RA as well as in various different diseases.
- 4) Bioinformatic studies predicts good targets during disease condition and many studies are reported leading to effective drug targets from the past 5-10 years. The view of the bioinformatics approach gives the idea of a molecule like inhibitors etc. leading to wet lab validation. Bioinformatics studies therefore could have been incorporated in this review.
- 5) There are many studies based on Traditional Chinese medicine and Indian herbs, fruits, medicinal plants etc. leading to reduction of RA inflammation, could also have been included in this review.